Biomarker Investigation for Early Gastric Cancer Detection

GASTROTRACK is a prospective, single-center clinico-biological cohort study evaluating non-invasive biomarkers for gastric and gastroesophageal junction adenocarcinomas (GEC). Saliva, gastric juice, plasma, and tumor tissue samples will be collected from patients undergoing upper gastrointestinal endoscopy. The study aims to identify molecular and microbial biomarkers associated with cancer diagnosis. Disease monitoring and relapse risk will be evaluated through integration of blood- and tissue-based analyses.

Inclusion Criteria: * I1. Patients ≥ 18 years at the day of signing informed consent. * I2. Patients referred for upper gastrointestinal endoscopy due to upper GI symptoms such as dysphagia, unexplained anemia, persistent dyspepsia or melena or following initial GEC diagnosis in another institution. * I3. Patients who have understood, dated, and signed the written voluntary informed consent form. * I4. Patients affiliated with or benefiting from medical insurance. Exclusion Criteria: * E1. Patients with known active malignancy. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer. * E2. Patients with known genetic predisposition such as Lynch syndrome or hereditary diffuse gastric cancer. * E3. Any condition contraindicating any procedure required by the protocol. * E4. Patients presenting a psychological, familial, geographical, or social situation that, in the investigator's judgment, could potentially prevent the signing of informed consent and/or compliance with study procedures. * E5. Pregnant or breast-feeding women.